{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:25:34Z","timestamp":1794651934186,"version":"4.9.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a rare and recently described entity associated with hereditary leiomyomatosis and RCC syndrome. FH-deficient RCC may show variable clinical and pathologic findings, but commonly presents with locally advanced and metastatic disease and carries a poor prognosis. We identified 32 patients with FH-deficient RCC, confirmed by FH immunohistochemistry (IHC) and\/or <jats:italic toggle=\"yes\">FH<\/jats:italic> mutation analysis, and performed a retrospective review of the clinical and pathologic features. Median age at presentation was 43 years (range, 18 to 69\u2009y), and the M:F ratio was 2.2:1. Median tumor size was 6.5\u2009cm (range, 2.5 to 28\u2009cm), and 71% presented at stage \u2265pT3a. After a median follow-up of 16 months (range, 1 to 118\u2009mo) in 26 patients, 19% showed no evidence of disease, 31% were alive with disease, and 50% were dead of disease. The vast majority of cases showed multiple histologic growth patterns, with papillary (52%) being the most common predominant pattern, followed by solid (21%), cribriform\/sieve-like (14%), sarcomatoid (3%), tubular (3%), cystic (3%), and low-grade oncocytic (3%). Viral inclusion-like macronucleoli with perinucleolar clearing were present in almost all cases (96%). All cases were evaluated using FH IHC, and 3 cases (9%) showed retained FH expression. Nineteen cases had germline or tumor mutation analysis confirming a <jats:italic toggle=\"yes\">FH<\/jats:italic> mutation, with 79% (11\/14) of cases showing mutations within coding regions and 21% (3\/14) showing mutations within intronic splice-sites. By IHC, 97% (32\/33) of cases were negative for CK7, 93% (27\/29) were negative for p63, and 52% (15\/29) were negative for GATA3. All cases stained were positive for PAX8 and showed retained succinate dehydrogenase B expression. Our overall findings show that FH-deficient RCC is considerably heterogenous in morphology and frequently behaves aggressively. Suspicion for this entity should be raised even in the absence of predominantly papillary architecture and characteristic nucleolar features. We have included cases with uncommonly seen features, including 4 cases with predominantly cribriform\/sieve-like architecture as well as one case with pure low-grade oncocytic morphology (9\u2009y of clinical follow-up without evidence of disease). Although FH IHC is a useful tool for identifying cases of FH-deficient RCC, not all cases of FH-deficient RCC show loss of FH staining, and <jats:italic toggle=\"yes\">FH<\/jats:italic> mutation analysis should be considered for patients with suspicious clinical or pathologic features, even in cases with retained FH IHC expression.<\/jats:p>","DOI":"10.1097\/pas.0000000000001372","type":"journal-article","created":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T05:44:58Z","timestamp":1568439898000},"page":"98-110","source":"Crossref","is-referenced-by-count":125,"title":["A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients"],"prefix":"10.1097","volume":"44","author":[{"given":"Hubert D.","family":"Lau","sequence":"first","affiliation":[{"name":"Veterans Affairs Palo Alto Health Care System, Department of Pathology, Palo Alto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice C.","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology, Stanford Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian A.","family":"Kunder","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford Medical Center, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R.","family":"Williamson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Wayne State University School of Medicine, Henry Ford Hospital, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad T.","family":"Idrees","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona M.","family":"Maclean","sequence":"additional","affiliation":[{"name":"Douglass Hanly Moir Pathology"},{"name":"Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Gill","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Sydney, Sydney, NSW, Australia"},{"name":"Royal North Shore Hospital, Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research"},{"name":"NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Sui","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford Medical Center, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/his.13727","article-title":"New and emerging renal entities: a perspective post-WHO 2016 classification","volume":"74","author":"Trpkov","year":"2019","journal-title":"Histopathology"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2007.01.155","article-title":"Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer","volume":"177","author":"Grubb","year":"2007","journal-title":"J Urol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/PAS.0000000000001000","article-title":"Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma","volume":"42","author":"Ohe","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.path.2018.07.010","article-title":"Recognizing hereditary renal cancers through the microscope: a pathology update","volume":"11","author":"Peng","year":"2018","journal-title":"Surg Pathol Clin"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10689-014-9735-2","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment","volume":"13","author":"Menko","year":"2014","journal-title":"Fam Cancer"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1073\/pnas.051633798","article-title":"Inherited susceptibility to uterine leiomyomas and renal cell cancer","volume":"98","author":"Launonen","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0002-9440(10)61757-9","article-title":"Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology","volume":"159","author":"Kiuru","year":"2001","journal-title":"Am J Pathol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/PAS.0b013e31804375b8","article-title":"The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome","volume":"31","author":"Merino","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","article-title":"Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry","volume":"38","author":"Chen","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/PAS.0000000000000617","article-title":"Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome","volume":"40","author":"Trpkov","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/PAS.0000000000000719","article-title":"Tubulocystic carcinoma of the kidney with poorly differentiated foci: a frequent morphologic pattern of fumarate hydratase\u2013deficient renal cell carcinoma","volume":"40","author":"Smith","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41379-018-0017-7","article-title":"Pattern multiplicity and fumarate hydratase (FH)\/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma from kidney tumors without FH gene alteration","volume":"31","author":"Muller","year":"2018","journal-title":"Mod Pathol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/PAP.0000000000000138","article-title":"Clinicopathologic and molecular pathology of collecting duct carcinoma and related renal cell carcinomas","volume":"24","author":"Seo","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.5858\/arpa.2018-0216-RA","article-title":"Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC): a contemporary review and practical discussion of the differential diagnosis for HLRCC-associated renal cell carcinoma","volume":"142","author":"Skala","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.2932","article-title":"Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status","volume":"225","author":"Bardella","year":"2011","journal-title":"J Pathol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.anndiagpath.2019.02.008","article-title":"Fumarate hydratase deficient renal cell carcinoma: chromosomal numerical aberration analysis of 12 cases","volume":"39","author":"Pivovarcikova","year":"2019","journal-title":"Ann Diagn Pathol"},{"issue":"suppl 6","key":"R18-20230922","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0959-8049(14)70131-5","article-title":"Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib","volume":"50","author":"Srinivasan","year":"2014","journal-title":"Eur J Cancer"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cge.13014","article-title":"Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers","volume":"92","author":"Muller","year":"2017","journal-title":"Clin Genet"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1399-0004.2010.01486.x","article-title":"Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis","volume":"79","author":"Smit","year":"2011","journal-title":"Clin Genet"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archderm.141.2.199","article-title":"Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome","volume":"141","author":"Alam","year":"2005","journal-title":"Arch Dermatol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1001\/archdermatol.2008.517","article-title":"Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer","volume":"144","author":"Stewart","year":"2008","journal-title":"Arch Dermatol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.juro.2012.07.139","article-title":"Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer","volume":"189","author":"Shuch","year":"2013","journal-title":"J Urol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/jmg.2005.036400","article-title":"Increased risk of cancer in patients with fumarate hydratase germline mutation","volume":"43","author":"Lehtonen","year":"2006","journal-title":"J Med Genet"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.humpath.2017.10.013","article-title":"The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes","volume":"71","author":"Udager","year":"2018","journal-title":"Hum Pathol"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"E2046","DOI":"10.1210\/jc.2014-1659","article-title":"Germline FH mutations presenting with pheochromocytoma","volume":"99","author":"Clark","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"13131","DOI":"10.1038\/ncomms13131","article-title":"Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets","volume":"7","author":"Chen","year":"2016","journal-title":"Nat Commun"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Linehan","year":"2016","journal-title":"N Engl J Med"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/his.13183","article-title":"A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma","volume":"71","author":"Smith","year":"2017","journal-title":"Histopathology"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/his.13395","article-title":"Re-evaluation of 33 \u201cunclassified\u201d eosinophilic renal cell carcinomas in young patients","volume":"72","author":"Li","year":"2018","journal-title":"Histopathology"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/his.13865","article-title":"Low\u2010grade oncocytic tumour of kidney (CD117\u2010negative, cytokeratin 7\u2010positive): a distinct entity?","volume":"75","author":"Trpkov","year":"2019","journal-title":"Histopathology"},{"key":"R33-20230922","first-page":"303872","article-title":"Abnormal cystic tumor in a patient with hereditary leiomyomatosis and renal cell cancer syndrome: evidence of a precursor lesion?","volume":"2015","author":"Ristau","year":"2015","journal-title":"Case Rep Urol"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2007.02.005","article-title":"Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway","volume":"11","author":"Pollard","year":"2007","journal-title":"Cancer Cell"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/PAS.0000000000000520","article-title":"Morphology and immunohistochemistry for 2SC and FH aid in detection of fumarate hydratase gene aberrations in uterine leiomyomas from young patients","volume":"39","author":"Joseph","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0000000000000573","article-title":"Fumarate hydratase deficient uterine leiomyomas occur in both the syndromic and sporadic settings","volume":"40","author":"Harrison","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/PAS.0b013e3181dc5e8a","article-title":"PAX8 (+)\/p63 (\u2212) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract","volume":"34","author":"Albadine","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/PAS.0b013e318216c112","article-title":"A comprehensive analysis of PAX8 expression in human epithelial tumors","volume":"35","author":"Laury","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2559.2011.04093.x","article-title":"p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system","volume":"60","author":"Carvalho","year":"2012","journal-title":"Histopathology"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.humpath.2012.12.012","article-title":"Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma","volume":"44","author":"Chang","year":"2013","journal-title":"Hum Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:51:10Z","timestamp":1695423070000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001372","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,12]]}}}